



## Supplementary Information

### eIF6 is a diagnostic and prognostic biomarker of poorer survival in cases of cutaneous melanoma


Zhang Fangyingnan<sup>1</sup>, Saquib Waheed<sup>2</sup>, Wu Jun<sup>1,2</sup>, Zhang Chao<sup>1\*</sup>, and Zhibin Li<sup>2\*</sup>




**Figure S1.** The GEPIA analysis of eIF6 expression in LGG, PAAD, KICH, LAMAL, and PCGP cancers.




**Figure S2. eIF6 level through all the stages of melanoma development.** The eIF6 expression level was analyzed via GEPIA.




**Figure S3. eIF6 level in skin melanoma and metastatic skin melanoma.** The eIF6 expression level was analyzed via TIMER.




**Figure S4.** Survival analysis of eIF6 down-stream genes.




**Figure S5.** Co-expression analysis of eIF6 in SKCM.



**Figure S6.** Correlation analysis between immune infiltration and eIF6 level in READ, SARC, SKCM, STAD, TGCT, THCA and THYM.




**Figure S7.** Correlation analysis between immune infiltration and eIF6 level in LGG, LIHC, LUAD, LUSC, MESO, OV, PAAD, PCPG and PRAD.




**Figure S8.** Correlation analysis between immune infiltration and eIF6 level in DLBC, ESCA, GBM, HNSC, KICH, KIRC and KIRP.





**Figure S9.** Correlation analysis between immune infiltration and eIF6 level in ACC, BLCA, BRCA, CESC, CHOL and COAD.



**Figure S10.** Correlation analysis between immune infiltration and eIF6 level in UCEC, UCS and

UVM.